Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan.
A previously healthy 47-year-old woman was treated for follicular lymphoma, grade III, with cyclophosphamide, adriamycin, vincristine, prednisone with rituximab (CHOP-R) followed by ibritumomab tiuxetan and rituximab. She developed a serum sickness-like illness during immunotherapy with fever, myalgias, arthralgias, and pleural and pericardial effusions. Despite anti-inflammatory therapies her symptoms persisted for 10 months before ultimate resolution. Her clinical course and literature are reviewed.
DeMonaco
Nicholas A
NA
Oncology-Hematology Associates, PA, Clinton, Maryland, USA.
Jacobs
Samuel A
SA
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001799:Blood Sedimentation / Q000187:drug effects; D002097:C-Reactive Protein / Q000096:biosynthesis / Q000187:drug effects; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D016499:Radioimmunotherapy / Q000009:adverse effects*; D000069283:Rituximab; D012713:Serum Sickness / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D013154:Spleen / Q000473:pathology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D002097:C-Reactive Protein; D011241:Prednisone; D007213:Indomethacin